“Top 15” List Predicts Best-Selling Cancer Drugs in 2022

January 18, 2017

FiercePharma has compiled a list of the top 15 cancer medications that are expected to dominate the oncology market in 2022. According to the report, oncology drugs remain the fastest-growing category in pharma, with anticipated sales of approximately $90 billion over the next five years.

Among the top six drugs on the list, three are from the highly touted programmed death-1/programmed death ligand-1 (PD-1/PD-L1) or checkpoint inhibitor class. Drugs in this class activate the immune system, enabling it to recognize cancer cells and destroy them.

However, while the checkpoint inhibitor class has ascended, nine of the 15 top-selling drugs in 2022 will still be monoclonal antibodies, FiercePharma predicts. First approved in the late 1990s, these therapies quickly became the preferred option for various cancers. Three of them—all first-generation cancer antibodies from Roche—are due to face biosimilar competition within the next couple of years.

Here are the 15 drugs that FiercePharma foresees as being the dominant players on the oncology scene in 2022:

Revlimid (lenalidomide, Celgene): Thalidomide analogue. Current indications: multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. New indications, including newly diagnosed multiple myeloma and non-Hodgkin’s lymphoma, are expected in the near future.
Opdivo (nivolumab, Bristol-Myers Squibb): PD-1 inhibitor. Current indications: non–small-cell lung cancer (NSCLC), metastatic melanoma, renal cell carcinoma, and classical Hodgkin’s lymphoma.
Imbruvica (ibrutinib, Pharmacyclics/Janssen): Kinase inhibitor. Current indications: chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia.
Keytruda (pembrolizumab, Merck): PD-1/PD-L1 inhibitor. Current indications: advanced melanoma, NSCLC, and head-and-neck squamous cell cancer.
Ibrance (palbociclib, Pfizer): Kinase inhibitor. Current indication: metastatic breast cancer.
Tecentriq (atezolizumab, Roche): PD-L1 inhibitor. Current indications: urothelial carcinoma and NSCLC.
Darzalex (daratumumab, Johnson & Johnson): CD38-directed cytolytic antibody. Current indication: multiple myeloma.
Perjeta (pertuzumab, Roche): Human epidermal growth factor receptor 2 (HER2)/neu receptor antagonist (antibody). Current indication: HER2-positive breast cancer.
Xtandi (enzalutamide, Astellas Pharma/Pfizer): Androgen receptor inhibitor. Current indication: advanced prostate cancer.
Avastin (bevacizumab, Genentech): Vascular endothelial growth factor-specific angiogenesis inhibitor (antibody). Current indications: colorectal cancer, NSCLC, ovarian cancer, cervical cancer, renal cell carcinoma, and glioblastoma.
Herceptin (trastuzumab, Genentech): HER2/neu receptor antagonist (antibody). Current indications: breast cancer and gastric cancer.
Gazyva (obinutuzumab, Genentech): CD20-directed cytolytic antibody. Current indications: CLL and follicular lymphoma.
Jakafi (ruxolitinib, Incyte/Novartis): Kinase inhibitor. Current indications: polycythemia vera and myelofibrosis.
Venclexta (venetoclax, AbbVie/Genentech): BCL-2 inhibitor (antibody). Current indication: CLL.
Rituxan (rituximab, Genentech): CD20-directed cytolytic antibody. Current indications: CLL and non-Hodgkin’s lymphoma.

Source: FiercePharma; January 17, 2017.

More Headlines

Kidney Disease Drug Wins Breakthrough Therapy Designation

Kappa opioid receptor agonist treats uremic pruritus during hemodialysis

FDA Approves Rituxan Hycela for Subcutaneous Injection in Certain Blood Cancers

SC formulation can be administered within five to seven minutes

Stem Cells: The Future of Medicine?

Scientists grow mice in a petri dish

Medicaid Cuts Put Rural Hospitals in the Crosshairs

For facilities serving the uninsured, survival depends on government help

Four Republican Senators Reject GOP Health Care Bill

Legislation lacks sufficient votes for passage

New Phase 3 Data on Shingles Vaccine Shingrix Presented at CDC Advisory Meeting

Immune response is noninferior to that of Zostavax

Health Care Providers Could Prevent Opioid-Related Deaths by Testing for Certain Genes, Scientists Claim

Investigators unravel pharmacogenetic effects on opioid analgesia

Reuters Poll: Most Americans Expect GOP Health Care Plan to Be Harmful

Original House bill gets “thumbs down”—critics brace for Senate version

More Than 500,000 Clinicians Will Be Hit With Medicare Penalty This Year

Charges could be as high as $2,000 for those who did not meet PQRS requirements

RWE is a relatively new kid on the block. How exactly it will fit into the complicated world of cancer drug testing, approval, regulation, and marketing is uncertain. The randomized clinical trial has been the gold standard in oncology research for decades and will remain so for the foreseeable future.

Drugs for Diabetes: It’s No Longer Just About Controlling Blood Sugar

The link between diabetes and cardiovascular disease has been clear for decades, but until 2015 no clinical trial had convincingly demonstrated a link between medications that lower blood glucose and cardiovascular risks. Enter SGKT2 inhibitors and GLP-1 agonists.

Orphan Drugs: Way Too Many, Way Too Expensive

Sales hit the billion dollar mark as pharmaceutical companies apply creative approaches to increase earnings. For instance, “salami slicing”: Dividing diseases into smaller and smaller categories based on genetic and biomarker differences so that the product can achieve the coveted orphan drug status.

Otis Brawley, MD
American Cancer Society

The Screening Debate — Affirmative: Cuts Cancer Mortality Negative: There’s No Hard Proof

To screen, or not to screen? For years, the question was rhetorical. Doctors screened, and health insurers anted up. The public still likes cancer screening, but some critics say that many tests have yet to show lifesaving benefit. The debate can get heated, as the mammography wars proved.

FDA Approves Tymlos for Osteoporosis in Postmenopausal Women

The FDA has given the green light to abaloparatide subcutaneous injection (Tymlos, Radius Health) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed on or are intolerant of other available osteoporosis therapy.

FDA Approves Radicava for ALS

The FDA has approved edaravone (Radicava, Mitsubishi Tanabe Pharma America, Inc.) for the treatment of patients with amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease.

Neil Minkoff, MD

Oncology Care Model Headed for Shades of Gray

Regardless of your politics, the motivation behind a program designed to curtail cancer costs is clear. Cancer epidemiology (the old are disproportionately affected), coupled with 21st century demography (longer life expectancy, aging boomers), means cancer costs are going up.

Venture Philanthropy Straddles Two Worlds

Venture philanthropy and the move toward investment of not-for-profit dollars in for-profit companies started about 10 years ago. One expert argues that it’s a little like calling someone an amateur-pro athlete. You can’t be both. Proponents, however, point to some initially impressive results especially for niche diseases.

7 Strategies for Improving Drug Utilization

When new pharmaceutical products enter the market, the lack of real-world experience with these drugs creates quandaries for payers and providers alike. Often, all there is to go on is the minimum required for FDA approval—non-inferiority to a comparator product in terms of efficacy and safety. Here are a few promising strategies to end this ambiguity.

Search form

“Top 15” List Predicts Best-Selling Cancer Drugs in 2022

More Headlines

Read Next